Folate status, regulatory T cells and MTHFR C677T polymorphism study in allergic children

Anna Socha-Banasiak1, Barbara Kamer1, Agnieszka Gach2

  • 1Gastroenterology, Allergology and Pediatric Department, Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland.

Insights

Early-life folate levels may influence regulatory T cell activity, potentially impacting allergy development in children. Lower folate was seen in children with food allergies and specific MTHFR gene variants.

Area of Science:

  • Pediatric Allergy and Immunology
  • Nutritional Immunology
  • Genetics and Immunology

Background:

  • Allergies are a growing concern in childhood.
  • Regulatory T (Treg) cells play a crucial role in immune tolerance.
  • Folate metabolism, influenced by MTHFR genotypes, is vital for immune function.

Purpose of the Study:

  • To investigate serum folate concentrations in allergic children.
  • To analyze the relationship between folate levels, Treg cell FoxP3 expression, and MTHFR genotypes.
  • To explore the potential role of folate status in childhood allergy development.

Main Methods:

  • Study included 83 allergic and 49 healthy children (2-72 months).
  • Measured serum folic acid, MTHFR C677T polymorphism, and Treg cell percentage.
  • Analyzed medical history and laboratory data.

Main Results:

  • Children with food allergy had higher serum folate than those with inhalant allergy (P=0.037).
  • TT homozygotes (MTHFR) showed lower folate levels than CC homozygotes (P=0.045).
  • A negative correlation between serum folate and Treg cell FoxP3 expression was observed (r=-0.339, P<0.05).

Conclusions:

  • Folate status may influence Treg cell function.
  • This suggests a potential role for folate in the development and progression of childhood allergies.
  • Further research into folate supplementation and allergy management is warranted.
Abstract

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
106
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
58